By Nancy Walsh, Staff Writer, MedPage TodayPublished: January 27, 2012Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco.
Action Points
Newer biologic agents for treating moderate-to-severe plaque psoriasis do not carry the risk of end-organ toxicities found with older, conventional systemic agents and can be considered for first-line use in some cases,
No comments:
Post a Comment